Dannielle et al. reported that the loss of HK2 could lead to an increase in OXPHOS, and the use of metformin in this process could simultaneously inhibit the activity of Complex I in OXPHOS, which can considerably reduce the drug resistance of tumour cells to sorafenib [155]. Here, HK2 is linked to neoplasm.